The Effect of Combination of Quercetin And Glibenclamide on Myocardial Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Expression In Type 2 Diabetic Rat
DOI:
https://doi.org/10.3329/bjms.v16i2.31943Keywords:
Quercetin, glibenclamide, Nuclear factor erythroid 2-related factor 2 (Nrf 2), immuno histochemistry, type 2 diabetes mellitusAbstract
Background. Diabetes mellitus (DM) is a metabolic disorder syndrome that marked by hyperglycemia. The main macrovascular complication is heart failure due to diabetic cardiomyopathy. Hyperglycemia can increase reactive oxygen species (ROS) and lipid peroxidation that induce cellular damage. Quercetin is an antioxidant that reduce hyperglycemia and ROS by modify the expression of nuclear factor erythroid 2-related factor 2 (Nrf 2).
Objective. The aim of this research was to investigate the effect of combination of quercetin and glibenclamide on myocardial nuclear factor erythroid 2-related factor 2 (nrf 2) expression in type 2 diabetic rat compared with no combination.
Methods. The rats were divided randomly into nine groups (each group consisted of four rats). The control group consist of a normal group that received placebo, DM control groups that received placebo and glibenclamide and intervention groups received quercetin 5, 20 and 80 mg/kgbw/day and combination of quercetin with 5 mg/kgbw/day of glibenclamide orally for a period of four weeks. The expression of myocardial Nrf 2 was measured by immunohistochemistry. Data was analyzed by ANOVA and p<0.05 was considered as significant. Results. Twenty and 80 mg/kgbw/day of quercetin with or without combination with glibenclamide orally for a period of four weeks increase myocardial Nrf2 expression higher than placebo (p<0.05). Eighty mg/kgbw/day of quercetin increase myocardial Nrf2 expression higher than 5 and 20 mg/kgbw/day (p<0.05).
Conclusion. From this study it can be suggested that there are significant different in expression level of myocardial Nrf2 of type 2 DM after a combination of quercetin and glibenclamide, quercetin alone, glibenclamide alone and placebo.
Bangladesh Journal of Medical Science Vol.16(2) 2017 p.302-306
Downloads
23
26
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:
- Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.
Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.- Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.